GGrantIndex
← Leaderboards

Massimo F Loda

Dana-Farber Cancer Institute

$16,725,588
Attributed
$18,790,822
Total exposure
16
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY200725
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$31,834,990 · 18

By mechanism

P50$21,211,941 · 9
R01$6,918,348 · 3
P01$3,351,250 · 2
P20$346,387 · 1
P41$7,064 · 1
P30$0 · 2

Top collaborators

Most similar at Dana-Farber Cancer Institute

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorTissuesResearch PersonnelMolecularBaseMalignant Neoplasm Of ProstateSamplingLinkPathologySpecimenMouse ModelHuman TissueTissue SamplePathologicResourcesProstateTechnologyCollaborationsFreezingCellsCollectionServicesProteinsCohort

Grant awards (69)

Core A: Pathobiology Core$396,282
P01 · FY2025 · CA · contact PI
Core A: Pathobiology Core$382,412
P01 · FY2024 · CA · contact PI
Core A: Pathobiology Core$408,681
P01 · FY2023 · CA · contact PI
Core A: Pathobiology Core$553,798
P01 · FY2022 · CA · contact PI
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer$2,122,802
P50 · FY2021 · CA · contact PI
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer$2,168,456
P50 · FY2020 · CA · contact PI
Precision Interception of Aggressive Prostate Cancer in African American Men$116,098
P20 · FY2020 · CA · contact PI
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer$2,122,802
P50 · FY2019 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$537,433
R01 · FY2019 · CA
Precision Interception of Aggressive Prostate Cancer in African American Men$99,998
P20 · FY2019 · CA · contact PI
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer$2,283,108
P50 · FY2018 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2018 · CA
Molecular Link Between Metabolic Syndrome and Prostate Cancer$384,420
R01 · FY2018 · CA · contact PI
Precision Interception of Aggressive Prostate Cancer in African American Men$130,291
P20 · FY2018 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2017 · CA
Molecular Link Between Metabolic Syndrome and Prostate Cancer$382,955
R01 · FY2017 · CA · contact PI
Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress$266,838
P50 · FY2017 · CA · contact PI
Tissue and Pathology Core$264,666
P50 · FY2017 · CA · contact PI
Tissue and Pathology Core$263,457
P50 · FY2017 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,162,000
P50 · FY2016 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2016 · CA
Molecular Link Between Metabolic Syndrome and Prostate Cancer$377,253
R01 · FY2016 · CA · contact PI
Tissue and Pathology Core$247,839
P50 · FY2016 · CA · contact PI
Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress$243,036
P50 · FY2016 · CA · contact PI
Tissue and Pathology Core$240,833
P50 · FY2016 · CA · contact PI
DF/HCC SPORE in Prostate Cancer$2,185,000
P50 · FY2015 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2015 · CA
Molecular Link Between Metabolic Syndrome and Prostate Cancer$377,253
R01 · FY2015 · CA · contact PI
Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress$264,886
P50 · FY2015 · CA · contact PI
Tissue and Pathology Core$254,652
P50 · FY2015 · CA · contact PI
Tissue and Pathology Core$239,458
P50 · FY2015 · CA · contact PI
Molecular Link Between Metabolic Syndrome and Prostate Cancer$377,216
R01 · FY2014 · CA · contact PI
Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress$268,076
P50 · FY2014 · CA · contact PI
Tissue and Pathology Core$246,964
P50 · FY2014 · CA · contact PI
Tissue and Pathology Core$231,987
P50 · FY2014 · CA · contact PI
Tissue and Pathology Core$302,738
P50 · FY2013 · CA · contact PI
Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress$261,382
P50 · FY2013 · CA · contact PI
Tissue and Pathology Core$241,133
P50 · FY2013 · CA · contact PI
CA: Tissue and Pathology$684,809
P50 · FY2012 · CA · contact PI
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer$339,794
R01 · FY2012 · CA · contact PI
CA: Tissue and Pathology$662,390
P50 · FY2011 · CA · contact PI
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer$339,794
R01 · FY2011 · CA · contact PI
Pathology Core$296,624
P01 · FY2011 · CA · contact PI
Tissue and Pathology Resources$197,589
P50 · FY2011 · CA · contact PI
CA: Tissue and Pathology$693,759
P50 · FY2010 · CA · contact PI
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer$350,303
R01 · FY2010 · CA · contact PI
Pathology Core$307,872
P01 · FY2010 · CA · contact PI
Tissue and Pathology Resources$217,880
P50 · FY2010 · CA · contact PI
PALMITOYLATION SIGNATURE IN PROSTATE CANCER CELL LINES$7,064
P41 · FY2010 · RR · contact PI
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer$350,303
R01 · FY2009 · CA · contact PI
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer$330,713
R01 · FY2009 · CA · contact PI
Pathology Core$303,930
P01 · FY2009 · CA · contact PI
Core 3$263,236
P50 · FY2009 · CA · contact PI
CA: Tissue and Pathology$263,032
P50 · FY2009 · CA · contact PI
Tissue and Pathology Resources$215,898
P50 · FY2009 · CA · contact PI
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer$350,303
R01 · FY2008 · CA · contact PI
Pathology Core$297,911
P01 · FY2008 · CA · contact PI
Core 3$263,237
P50 · FY2008 · CA · contact PI
CA: Tissue and Pathology$208,241
P50 · FY2008 · CA · contact PI
Tissue and Pathology Resources$207,986
P50 · FY2008 · CA · contact PI
Pathology Core$300,063
P01 · FY2007 · CA · contact PI
Core 3$263,024
P50 · FY2007 · CA · contact PI
Tissue and Pathology Resources$188,747
P50 · FY2007 · CA · contact PI
Core--Pathology$103,677
P01 · FY2002 · CA
Core--Tissue and pathology$0
P50 · FY2002 · CA
Core--Pathology$0
P01 · FY2001 · CA
ISOPEPTIDASES UBIQUITIN DEGRADATION AND PROSTATE CANCER$204,396
R01 · FY2000 · CA
CORE--HUMAN PROSTATE CANCER PATHOLOGY$0
P30 · FY2000 · CA
CORE--IN SITU HYBRIDIZATION$0
P30 · FY2000 · CA